GlassScriptPhysician profile
Anna Allman
NPI 1427328681
$2,346.70
in general payments reported to CMS, 2019-2025
25 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,221 · 2022: $573 · 2023: $261 · 2024: $114 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.73 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $297.39 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $271.20 | 2021-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.03 | 2021-2024 | Jardiance |
| Abbvie INC. | $180.14 | 2021-2022 | |
| Esperion Therapeutics, INC. | $169.16 | 2021 | |
| Glaxosmithkline, LLC. | $156.27 | 2021-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $90.76 | 2021 | |
| Merck Sharp & Dohme LLC | $61.75 | 2021 | |
| Nestle Healthcare Nutrition INC. | $58.35 | 2021-2022 | |
| Pfizer INC. | $56.82 | 2021-2022 | |
| Amgen INC. | $52.11 | 2021-2023 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $42.15 | 2021-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.09 | 2021-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $29.76 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.12 | 2025 | Fruzaqla |
| Dexcom, INC. | $28.36 | 2021 | |
| Avanir Pharmaceuticals, INC. | $25.04 | 2022 | |
| Shield Therapeutics INC | $24.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.58 | 2022 | |
| Forte Bio-Pharma LLC | $17.08 | 2021-2022 | |
| Eisai INC. | $13.61 | 2021 | |
| Abbott Laboratories | $12.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Allman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.